.

BioPharmaceutical Business Intelligence

  • Identify first generic entrants
  • Uncover prior art in expired and abandoned patents
  • Drug patents in 130+ countries

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

Teva
Harvard Business School
Queensland Health
Moodys
Fish and Richardson
Mallinckrodt
Federal Trade Commission
Fuji
Chubb
Express Scripts

Generated: September 22, 2017

DrugPatentWatch Database Preview

ENSTILAR Drug Profile

« Back to Dashboard

Which patents cover Enstilar, and what generic Enstilar alternatives are available?

Enstilar is a drug marketed by Leo Pharma As and is included in one NDA. There are two patents protecting this drug.

This drug has seventy-three patent family members in thirty-two countries.

The generic ingredient in ENSTILAR is betamethasone dipropionate; calcipotriene. There are sixty-six drug master file entries for this compound. One supplier is listed for this compound. Additional details are available on the betamethasone dipropionate; calcipotriene profile page.

Summary for Tradename: ENSTILAR

Patents:2
Applicants:1
NDAs:1
Suppliers / Packagers: see list1
Clinical Trials: see list2
Formulation / Manufacturing:see details
Drug Prices:see details
DailyMed Link:ENSTILAR at DailyMed

Pharmacology for Tradename: ENSTILAR

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Leo Pharma As
ENSTILAR
betamethasone dipropionate; calcipotriene
AEROSOL, FOAM;TOPICAL207589-001Oct 16, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Pharma As
ENSTILAR
betamethasone dipropionate; calcipotriene
AEROSOL, FOAM;TOPICAL207589-001Oct 16, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Leo Pharma As
ENSTILAR
betamethasone dipropionate; calcipotriene
AEROSOL, FOAM;TOPICAL207589-001Oct 16, 2015RXYesYes► Subscribe► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Non-Orange Book Patents for Tradename: ENSTILAR

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,566,286Pharmaceutical spray composition comprising a vitamin D analogue and a corticosteroid► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Tradename: ENSTILAR

Country Document Number Estimated Expiration
Norway329486► Subscribe
European Patent Office3146969► Subscribe
MexicoPA01010676► Subscribe
Canada2800181► Subscribe
European Patent Office2455083► Subscribe
European Patent Office1178808► Subscribe
Spain2388425► Subscribe
Mexico2012013591► Subscribe
Slovenia1178808► Subscribe
Czech Republic303142► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Chubb
Baxter
Harvard Business School
US Department of Justice
Deloitte
Julphar
Mallinckrodt
Healthtrust
QuintilesIMS
Covington

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot